Treatment with placental growth factor attenuates myocardial ischemia/reperfusion injury.
Yabing ZhangChang CaoJuan XinPeilin LvDongxu ChenShiyue LiHui YangChan ChenBin LiuQian LiPublished in: PloS one (2018)
Studies have established that oxidative stress plays an important role in the pathology of myocardial ischemia/reperfusion injury (MIRI). Vascular endothelial growth factor receptor 1 (VEGFR1) activation was reported to reduce oxidative stress and apoptosis. In the present study, we tested the hypothesis that the activation of VEGFR1 by placental growth factor (PlGF) could reduce MIRI by regulating oxidative stress. Mouse hearts and neonatal mouse cardiomyocytes were subjected to ischemia/reperfusion (I/R) and oxygen glucose deprivation (OGD), respectively. PlGF pretreatment markedly ameliorated I/R injury, as demonstrated by reduced infarct size and improved cardiac function. The protection was associated with a reduction of cardiomyocyte apoptosis. Similarly, our in vitro study showed that PlGF treatment improved cell viability and reduced cardiomyocyte apoptosis. Also, activation of VEGFR1 by PlGF suppressed intracellular and mitochondrial reactive oxygen species (ROS) generation. However, VEGFR1 neutralizing monoclonal antibody, which preventing PlGF binding, totally blocked this protective effect. In conclusion, activation of VEGFR1 could protect heart from I/R injury by suppression of oxidative stress and apoptosis.
Keyphrases
- oxidative stress
- vascular endothelial growth factor
- growth factor
- ischemia reperfusion injury
- reactive oxygen species
- dna damage
- diabetic rats
- induced apoptosis
- endothelial cells
- left ventricular
- heart failure
- endoplasmic reticulum stress
- high glucose
- type diabetes
- angiotensin ii
- blood glucose
- heat shock
- cell proliferation
- blood pressure
- atrial fibrillation
- acute myocardial infarction
- binding protein
- signaling pathway
- insulin resistance
- smoking cessation
- dna binding